Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients

NCT04345523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

350

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

OTHER: Blood and derivatives.
DRUG: Standard of Care

Sponsor

Cristina Avendaño Solá

Collaborators

[object Object]